TC-2559
TC-2559 is an orally active, selective central nervous system Nicotinic acetylcholine receptor agonist with a Ki value of 5 nM. TC-2559 activates central nervous system receptors selectively over peripheral nervous system receptors. TC-2559 improves scopolamine (HY-N0296)-induced cognitive impairment and enhances radial arm maze performance. TC-2559 can be used in the research of neurodegenerative diseases.
For research use only. We do not sell to patients.
- CAS No.: 326924-19-0
- Formula: C12H18N2O·1/2C6H10O8
- Molecular Weight:311.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
TC-2559 binds with high affinity to nicotinic acetylcholine receptors in rat brain cortex membranes, with a Ki of 5.5 nM[1].
TC-2559 (0.01-100 μM) potently and efficaciously stimulates dopamine release from rat striatal synaptosomes (EC50 = 203 nM) and induces significantly less residual inhibition of dopamine release than nicotine following pre-incubation[1].
TC-2559 (0.01-90 μM) potently stimulates 86Rb+ efflux from rat thalamic synaptosomes, with an EC50 of 367 nM and efficacy comparable to nicotine[1].
TC-2559 (10 μM; 2 h) significantly protects cultured fetal rat brain cells from glutamate-induced neurotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
TC-2559 (1-10 μmol/kg; p.o.; single administration or daily administration for 6 consecutive days) enhances radial arm maze working memory performance in male Sprague-Dawley rats (acute administration), improves their reference memory at an acute dose of 1 μmol/kg, and repeated oral administration (1-6 μmol/kg) further enhances their working memory performance[1].
TC-2559 (1-10 μmol/kg; subcutaneous injection; single administration) induces dose-dependent hypoactivity in male Sprague-Dawley rats. A dose of 1 μmol/kg produces a persistent effect, and both 1 μmol/kg and 10 μmol/kg doses significantly reduce locomotor activity over 30 minutes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 200-350 g, scopolamine-induced amnesia)[1]
-
Dosage:0.6 μmol/kg; 1 μmol/kg; 3 μmol/kg; 6 μmol/kg; 10 μmol/kg
-
Administration:s.c.; single dose
-
Result:Significantly attenuated scopolamine-induced reduction in step-through retention latencies at 3 μmol/kg (median latency 88.7 s) and 6 μmol/kg (median latency 105.7 s).
Did not produce statistically significant attenuation at 0.6 μmol/kg, 1 μmol/kg, and 10 μmol/kg compared to scopolamine alone.
Chemical Information
-
CAS No. 326924-19-0
-
Molecular Weight 311.30
-
Formula C12H18N2O·1/2C6H10O8
-
SMILES
OC([C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C(O)=O)=O.CNCC/C=C/C1=CN=CC(OCC)=C1.[1/2]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TC-2559 Related Classifications
Cat. No.: HY-183204
Powered by Bioz
- TC-2559
- 326924-19-0
- TC2559
- TC 2559
- nAChR
- scopolamine-induced cognitive deficits
- TE671/RD cells
- CNS nicotinic acetylcholine receptor
- PNS receptors
- dopamine
- ganglion-type nicotinic acetylcholine receptors
- muscle-type nicotinic acetylcholine receptors
- glutamate-induced neurotoxicity
- PC12 cells
- radial arm maze
- Inhibitor
- inhibitor
- inhibit